<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Cytotoxics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i500.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i500.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i500.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i995.htm" title="Previous: Cranberry Juice">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1205.htm" title="Next: Eribulin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i500">Cytotoxics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Cytotoxics</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of  cytotoxics with clozapine (increased risk of agranulocytosis)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr></tbody></table><p><b>Eribulin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  eribulin possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  eribulin possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  eribulin possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  eribulin possibly reduced by St John's wort </td><td></td></tr></tbody></table><p><b>Vinflunine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  vinflunine possibly increased by grapefruit juice—manufacturer of vinflunine advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  vinflunine possibly increased by itraconazole—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  vinflunine increased by ketoconazole—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  vinflunine possibly reduced by rifampicin—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  vinflunine possibly increased by ritonavir—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  vinflunine possibly reduced by St John's wort—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Arsenic Trioxide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>risk of ventricular arrhythmias with  arsenic trioxide increased by hypokalaemia caused by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with amitriptyline </b></td><td></td></tr><tr><td><a href="41001i290.htm">Amphotericin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with amphotericin </b></td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i244.htm">Clomipramine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with clomipramine </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with disopyramide </b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>risk of ventricular arrhythmias with  arsenic trioxide increased by hypokalaemia caused by loop diuretics </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td class="cBV"><b>risk of ventricular arrhythmias with  arsenic trioxide increased by hypokalaemia caused by thiazides and related diuretics </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with haloperidol </b></td><td></td></tr><tr><td><a href="41001i840.htm">Levofloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with levofloxacin </b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with lithium </b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with moxifloxacin </b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  arsenic trioxide given with sotalol </b></td><td></td></tr></tbody></table><p><b>Dacarbazine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i21.htm">Aldesleukin</a></td><td class="cBV"><b>avoidance of  dacarbazine advised by manufacturer of aldesleukin </b></td><td></td></tr></tbody></table><p><b>Bortezomib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  bortezomib increased by ketoconazole </td><td></td></tr></tbody></table><p><b>Trabectedin</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Protein Kinase Inhibitors</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Pazopanib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with atazanavir </b></td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  pazopanib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with indinavir </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with ketoconazole </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td>plasma concentration of  pazopanib increased by lapatinib </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with nelfinavir </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with saquinavir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Gefitinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  gefitinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with carbamazepine </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of  gefitinib increased by itraconazole </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with phenytoin </td><td></td></tr><tr><td><a href="41001i747.htm">Ranitidine</a></td><td class="cBV"><b>plasma concentration of  gefitinib reduced by ranitidine </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  gefitinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with St John's wort </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> gefitinib possibly enhances anticoagulant effect of warfarin </b></td><td></td></tr></tbody></table><p><b>Everolimus</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by atazanavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by clarithromycin—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by darunavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>manufacturer of  everolimus advises avoid concomitant use with grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by indinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by itraconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by nelfinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by posaconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  everolimus reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by ritonavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by saquinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  everolimus possibly reduced by St John's wort—manufacturer of everolimus advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by telithromycin—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>plasma concentration of both drugs may increase when  everolimus given with verapamil </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by voriconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Temsirolimus</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><div>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of active metabolite of  temsirolimus increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of active metabolite of  temsirolimus reduced by rifampicin—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Lapatinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  lapatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  lapatinib reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td>possible increased risk of neutropenia when  lapatinib given with docetaxel </td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  lapatinib possibly reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> lapatinib increases plasma concentration of active metabolite of irinotecan—consider reducing dose of irinotecan</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  lapatinib increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i517.htm">Paclitaxel</a></td><td class="cBV"><b>increased risk of neutropenia when  lapatinib given with paclitaxel </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td> lapatinib increases plasma concentration of pazopanib </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with phenytoin </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with pimozide </b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with posaconazole </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  lapatinib possibly reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with repaglinide </b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with rifabutin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with saquinavir </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with St John's wort </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Nilotinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  nilotinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  nilotinib increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> nilotinib increases plasma concentration of midazolam </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  nilotinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Sunitinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  sunitinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>metabolism of  sunitinib inhibited by ketoconazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  sunitinib accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr></tbody></table><p><b>Sorafenib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  sorafenib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> sorafenib possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td> sorafenib increases plasma concentration of docetaxel </td><td></td></tr><tr><td><a href="41001i506.htm">Doxorubicin</a></td><td> sorafenib possibly increases plasma concentration of doxorubicin </td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td> sorafenib possibly increases plasma concentration of irinotecan </td><td></td></tr><tr><td><a href="41001i133.htm">Neomycin</a></td><td>bioavailability of  sorafenib reduced by neomycin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  sorafenib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Imatinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>












<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  imatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> imatinib possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  imatinib increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> imatinib possibly reduces plasma concentration of levothyroxine </td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by oxcarbazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i59.htm">Paracetamol</a></td><td>manufacturer of  imatinib advises caution with paracetamol </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by phenytoin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> imatinib increases plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td>manufacturer of  imatinib advises replacement of warfarin with a heparin (possibility of enhanced warfarin effect)</td><td></td></tr></tbody></table><p><b>Erlotinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















<tr><td><a href="41001i110.htm">Antacids</a></td><td class="cBV"><b>plasma concentration of  erlotinib possibly reduced by antacids—give antacids at least 4 hours before or 2 hours after erlotinib</b></td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  erlotinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i923.htm">Capecitabine</a></td><td>plasma concentration of  erlotinib possibly increased by capecitabine </td><td>Capecitabine is a prodrug of fluorouracil</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with cimetidine </b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  erlotinib increased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b>increased risk of bleeding when  erlotinib given with coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with esomeprazole </b></td><td></td></tr><tr><td><a href="41001i745.htm">Famotidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with famotidine </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>metabolism of  erlotinib inhibited by ketoconazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with lansoprazole </b></td><td></td></tr><tr><td><a href="41001i746.htm">Nizatidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with nizatidine </b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>increased risk of bleeding when  erlotinib given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  erlotinib reduced by omeprazole—manufacturer of erlotinib advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i754.htm">Pantoprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with pantoprazole </b></td><td></td></tr><tr><td><a href="41001i869.htm">Rabeprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with rabeprazole </b></td><td></td></tr><tr><td><a href="41001i747.htm">Ranitidine</a></td><td class="cBV"><b>plasma concentration of  erlotinib reduced by ranitidine—manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  erlotinib accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr></tbody></table><p><b>Dasatinib</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  dasatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i745.htm">Famotidine</a></td><td>plasma concentration of  dasatinib possibly reduced by famotidine </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  dasatinib possibly increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  dasatinib accelerated by rifampicin (reduced plasma concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> dasatinib possibly increases plasma concentration of simvastatin </td><td></td></tr></tbody></table><p><b>Vinorelbine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>possible increased risk of neutropenia when  vinorelbine given with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>metabolism of  vinorelbine possibly inhibited by itraconazole (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table><p><b>Mitotane</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> mitotane possibly reduces anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i549.htm">Spironolactone</a></td><td>manufacturer of  mitotane advises avoid concomitant use of spironolactone (antagonism of effect)</td><td></td></tr></tbody></table><p><b>Hydroxycarbamide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i397.htm">Didanosine</a></td><td class="cBV"><b>increased risk of toxicity when  hydroxycarbamide given with didanosine—avoid concomitant use</b></td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i401.htm">Stavudine</a></td><td class="cBV"><b>increased risk of toxicity when  hydroxycarbamide given with stavudine—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Bexarotene</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i599.htm">Gemfibrozil</a></td><td class="cBV"><b>plasma concentration of  bexarotene increased by gemfibrozil—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Etoposide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i431.htm">Atovaquone</a></td><td>plasma concentration of  etoposide possibly increased by atovaquone </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td>plasma concentration of  etoposide possibly increased by ciclosporin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> etoposide possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  etoposide possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  etoposide possibly reduced by phenytoin </td><td></td></tr></tbody></table><p><b>Irinotecan</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>metabolism of  irinotecan possibly inhibited by atazanavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  irinotecan and its active metabolite reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  irinotecan reduced by ketoconazole (but concentration of active metabolite of irinotecan increased)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>plasma concentration of active metabolite of  irinotecan increased by lapatinib—consider reducing dose of irinotecan</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  irinotecan and its active metabolite reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  irinotecan and its active metabolite reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td>plasma concentration of  irinotecan possibly increased by sorafenib </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>metabolism of  irinotecan accelerated by St John's wort (reduced plasma concentration—avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Vinblastine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i21.htm">Aldesleukin</a></td><td class="cBV"><b>avoidance of  vinblastine advised by manufacturer of aldesleukin </b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>toxicity of  vinblastine increased by erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>metabolism of  vinblastine possibly inhibited by posaconazole (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  vinblastine possibly increased by ritonavir </td><td></td></tr></tbody></table><p><b>Alkylating Drugs</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Bendamustine</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Estramustine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i461.htm">Sodium Clodronate</a></td><td class="cBV"><b>plasma concentration of  estramustine increased by sodium clodronate </b></td><td></td></tr></tbody></table><p><b>Carmustine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>myelosuppressive effects of   carmustine possibly enhanced by cimetidine </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> carmustine possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr></tbody></table><p><b>Lomustine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>myelosuppressive effects of   lomustine possibly enhanced by cimetidine </td><td></td></tr></tbody></table><p><b>Busulfan</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i302.htm">Itraconazole</a></td><td>metabolism of  busulfan inhibited by itraconazole (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i170.htm">Metronidazole</a></td><td class="cBV"><b>plasma concentration of  busulfan increased by metronidazole (increased risk of toxicity)</b></td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i59.htm">Paracetamol</a></td><td>metabolism of <i>intravenous</i>  busulfan possibly inhibited by paracetamol (manufacturer of <i>intravenous</i> busulfan advises caution within 72 hours of paracetamol)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  busulfan possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i1041.htm">Tioguanine</a></td><td>increased risk of hepatotoxicity when  busulfan given with tioguanine </td><td></td></tr></tbody></table><p><b>Cyclophosphamide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i480.htm">Digoxin</a></td><td> cyclophosphamide possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>side-effects of  cyclophosphamide possibly increased by itraconazole </td><td></td></tr><tr><td><a href="41001i513.htm">Pentostatin</a></td><td class="cBV"><b>increased toxicity when high-dose  cyclophosphamide given with pentostatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> cyclophosphamide enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Ifosfamide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i877.htm">Cisplatin</a></td><td>increased risk of otoxicity when  ifosfamide given with cisplatin </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ifosfamide possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr></tbody></table><p><b>Melphalan</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  melphalan given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> melphalan possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i196.htm">Nalidixic Acid</a></td><td>increased risk of  melphalan toxicity when given with nalidixic acid </td><td></td></tr></tbody></table><p><b>Thiotepa</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> thiotepa enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Antibiotics (cytotoxic)</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Mitoxantrone</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td>excretion of  mitoxantrone reduced by ciclosporin (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Idarubicin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  idarubicin increased by ciclosporin </b></td><td></td></tr></tbody></table><p><b>Mitomycin</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Epirubicin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  epirubicin increased by ciclosporin </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  epirubicin increased by cimetidine </b></td><td></td></tr></tbody></table><p><b>Bleomycin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i877.htm">Cisplatin</a></td><td class="cBV"><b>increased pulmonary toxicity when  bleomycin given with cisplatin </b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> bleomycin possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr></tbody></table><p><b>Doxorubicin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of neurotoxicity when  doxorubicin given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> doxorubicin possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td>plasma concentration of  doxorubicin possibly increased by sorafenib </td><td></td></tr><tr><td><a href="41001i401.htm">Stavudine</a></td><td> doxorubicin possibly inhibits effects of stavudine </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  doxorubicin possibly increased by verapamil </td><td></td></tr></tbody></table><p><b>Antimetabolites</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Pemetrexed</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>antifolate effect of  pemetrexed increased by pyrimethamine </b></td><td></td></tr></tbody></table><p><b>Raltitrexed</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i860.htm">Folates</a></td><td class="cBV"><b>manufacturer of  raltitrexed advises avoid concomitant use with folates </b></td><td></td></tr></tbody></table><p><b>Gemcitabine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i222.htm">Warfarin</a></td><td> gemcitabine possibly enhances anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Tioguanine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i993.htm">Busulfan</a></td><td>increased risk of hepatotoxicity when  tioguanine given with busulfan </td><td></td></tr></tbody></table><p><b>Cytarabine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i480.htm">Digoxin</a></td><td> cytarabine possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i820.htm">Flucytosine</a></td><td> cytarabine possibly reduces plasma concentration of flucytosine </td><td></td></tr><tr><td><a href="41001i508.htm">Fludarabine</a></td><td>intracellular concentration of  cytarabine increased by fludarabine </td><td></td></tr></tbody></table><p><b>Fludarabine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i821.htm">Cytarabine</a></td><td> fludarabine increases intracellular concentration of cytarabine </td><td></td></tr><tr><td><a href="41001i362.htm">Dipyridamole</a></td><td>effects of  fludarabine possibly reduced by dipyridamole </td><td></td></tr><tr><td><a href="41001i513.htm">Pentostatin</a></td><td class="cBV"><b>increased pulmonary toxicity when  fludarabine given with pentostatin (unacceptably high incidence of fatalities)</b></td><td></td></tr></tbody></table><p><b>Fluorouracil</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  fluorouracil inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fluorouracil enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i565.htm">Filgrastim</a></td><td>neutropenia possibly exacerbated when  fluorouracil given with filgrastim </td><td></td></tr><tr><td><a href="41001i170.htm">Metronidazole</a></td><td>metabolism of  fluorouracil inhibited by metronidazole (increased toxicity)</td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> fluorouracil possibly inhibits metabolism of phenytoin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i957.htm">Temoporfin</a></td><td class="cBV"><b>increased skin photosensitivity when <i>topical</i>  fluorouracil used with temoporfin </b></td><td></td></tr></tbody></table><p><b>Capecitabine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><div>Capecitabine is a prodrug of fluorouracil</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i22.htm">Allopurinol</a></td><td class="cBV"><b>manufacturer of  capecitabine advises avoid concomitant use with allopurinol </b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> capecitabine possibly increases plasma concentration of erlotinib </td><td></td></tr></tbody></table><p><b>Tegafur with uracil</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><div>Tegafur is a prodrug of fluorouracil</div><p><b>Mercaptopurine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i22.htm">Allopurinol</a></td><td class="cBV"><b>enhanced effects and increased toxicity of  mercaptopurine when given with allopurinol (reduce dose of mercaptopurine to one quarter of usual dose)</b></td><td></td></tr><tr><td><a href="41001i928.htm">Aminosalicylates</a></td><td>possible increased risk of leucopenia when  mercaptopurine given with aminosalicylates </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> mercaptopurine possibly reduces anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1178.htm">Febuxostat</a></td><td class="cBV"><b>avoidance of  mercaptopurine advised by manufacturer of febuxostat </b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td class="cBV"><b>increased risk of haematological toxicity when  mercaptopurine given with sulfamethoxazole (as co-trimoxazole)</b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased risk of haematological toxicity when  mercaptopurine given with trimethoprim (also with co-trimoxazole)</b></td><td></td></tr></tbody></table><p><b>Methotrexate</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td>excretion of  methotrexate increased by alkaline urine due to acetazolamide </td><td></td></tr><tr><td><a href="41001i683.htm">Acitretin</a></td><td class="cBV"><b>plasma concentration of  methotrexate increased by acitretin (also increased risk of hepatotoxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>excretion of  methotrexate reduced by aspirin (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>risk of toxicity when  methotrexate given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>excretion of  methotrexate possibly reduced by ciprofloxacin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i877.htm">Cisplatin</a></td><td class="cBV"><b>increased pulmonary toxicity when  methotrexate given with cisplatin </b></td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td class="cBV"><b>excretion of  methotrexate reduced by diclofenac (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> methotrexate possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td>increased risk of  methotrexate toxicity when given with doxycycline </td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by ibuprofen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i70.htm">Indometacin</a></td><td class="cBV"><b>excretion of  methotrexate reduced by indometacin (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i71.htm">Ketoprofen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by ketoprofen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td class="cBV"><b>risk of toxicity when  methotrexate given with leflunomide </b></td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i74.htm">Meloxicam</a></td><td class="cBV"><b>excretion of  methotrexate reduced by meloxicam (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i76.htm">Naproxen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by naproxen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i133.htm">Neomycin</a></td><td>absorption of  methotrexate possibly reduced by neomycin </td><td></td></tr><tr><td><a href="41001i52.htm">Nitrous Oxide</a></td><td class="cBV"><b>antifolate effect of  methotrexate increased by nitrous oxide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>excretion of  methotrexate probably reduced by NSAIDs (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>excretion of  methotrexate possibly reduced by omeprazole (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i174.htm">Penicillins</a></td><td>excretion of  methotrexate reduced by penicillins (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>antifolate effect of  methotrexate increased by phenytoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  methotrexate reduced by probenecid (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>antifolate effect of  methotrexate increased by pyrimethamine </b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td class="cBV"><b>increased risk of haematological toxicity when  methotrexate given with sulfamethoxazole (as co-trimoxazole)</b></td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td>increased risk of  methotrexate toxicity when given with sulfonamides </td><td></td></tr><tr><td><a href="41001i216.htm">Tetracycline</a></td><td>increased risk of  methotrexate toxicity when given with tetracycline </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> methotrexate possibly increases plasma concentration of theophylline </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased risk of haematological toxicity when  methotrexate given with trimethoprim (also with co-trimoxazole)</b></td><td></td></tr></tbody></table><p><b>Pentostatin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i502.htm">Cyclophosphamide</a></td><td class="cBV"><b>increased toxicity when  pentostatin given with high-dose cyclophosphamide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i508.htm">Fludarabine</a></td><td class="cBV"><b>increased pulmonary toxicity when  pentostatin given with fludarabine (unacceptably high incidence of fatalities)</b></td><td></td></tr></tbody></table><p><b>Platinum Compounds</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td class="cBV"><b>increased risk of nephrotoxicity and possibly of ototoxicity when  platinum compounds given with aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i137.htm">Capreomycin</a></td><td>increased risk of nephrotoxicity and ototoxicity when  platinum compounds given with capreomycin </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>increased risk of nephrotoxicity and ototoxicity when  platinum compounds given with diuretics </td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td class="cBV"><b>increased risk of nephrotoxicity and possibly of ototoxicity when  platinum compounds given with polymyxins </b></td><td></td></tr></tbody></table><p><b>Carboplatin</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Cisplatin</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i21.htm">Aldesleukin</a></td><td class="cBV"><b>avoidance of  cisplatin advised by manufacturer of aldesleukin </b></td><td></td></tr><tr><td><a href="41001i1008.htm">Bleomycin</a></td><td class="cBV"><b>increased pulmonary toxicity when  cisplatin given with bleomycin </b></td><td></td></tr><tr><td><a href="41001i825.htm">Ifosfamide</a></td><td>increased risk of otoxicity when  cisplatin given with ifosfamide </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b>increased pulmonary toxicity when  cisplatin given with methotrexate </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> cisplatin possibly reduces plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>increased risk of nephrotoxicity and possibly of ototoxicity when  cisplatin given with vancomycin </td><td></td></tr></tbody></table><p><b>Oxaliplatin</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Procarbazine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i20.htm">Alcohol</a></td><td>disulfiram-like reaction when  procarbazine given with alcohol </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> procarbazine possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr></tbody></table><p><b>Temozolomide</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  temozolomide increased by valproate </td><td></td></tr></tbody></table><p><b>Vincristine</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i480.htm">Digoxin</a></td><td> vincristine possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>metabolism of  vincristine possibly inhibited by itraconazole (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td>metabolism of  vincristine possibly inhibited by nifedipine </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>metabolism of  vincristine possibly inhibited by posaconazole (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table><p><b>Taxanes</b> belongs to
      <b>Cytotoxics</b>
          but has no specific interaction information.
        </p><p><b>Cabazitaxel</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>
















<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with atazanavir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with carbamazepine </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with indinavir </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with ketoconazole </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with nelfinavir </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with phenytoin </b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with rifabutin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with saquinavir </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with St John's wort </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  cabazitaxel advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Docetaxel</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td><i>in vitro</i> studies suggest a possible interaction between  docetaxel and ciclosporin (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td><i>in vitro</i> studies suggest a possible interaction between  docetaxel and erythromycin (consult docetaxel product literature)</td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td><i>in vitro</i> studies suggest a possible interaction between  docetaxel and ketoconazole (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td>possible increased risk of neutropenia when  docetaxel given with lapatinib </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  docetaxel possibly increased by ritonavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td>plasma concentration of  docetaxel increased by sorafenib </td><td></td></tr></tbody></table><p><b>Paclitaxel</b> belongs to
      <b>Cytotoxics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>increased risk of neutropenia when  paclitaxel given with lapatinib </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  paclitaxel increased by nelfinavir </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  paclitaxel increased by ritonavir </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1205.htm" title="Eribulin">Eribulin</a></li><li><a href="41001i1181.htm" title="Vinflunine">Vinflunine</a></li><li><a href="41001i1168.htm" title="Arsenic Trioxide">Arsenic Trioxide</a></li><li><a href="41001i1167.htm" title="Dacarbazine">Dacarbazine</a></li><li><a href="41001i1116.htm" title="Bortezomib">Bortezomib</a></li><li><a href="41001i1103.htm" title="Trabectedin">Trabectedin</a></li><li id="_41001i1087"><a href="41001i1087.htm" title="Protein Kinase Inhibitors">Protein Kinase Inhibitors</a></li><li><a href="41001i1085.htm" title="Vinorelbine">Vinorelbine</a></li><li><a href="41001i1057.htm" title="Mitotane">Mitotane</a></li><li><a href="41001i1052.htm" title="Hydroxycarbamide">Hydroxycarbamide</a></li><li><a href="41001i1046.htm" title="Bexarotene">Bexarotene</a></li><li><a href="41001i1031.htm" title="Etoposide">Etoposide</a></li><li><a href="41001i1006.htm" title="Irinotecan">Irinotecan</a></li><li><a href="41001i1002.htm" title="Vinblastine">Vinblastine</a></li><li id="_41001i501"><a href="41001i501.htm" title="Alkylating Drugs">Alkylating Drugs</a></li><li id="_41001i505"><a href="41001i505.htm" title="Antibiotics (cytotoxic)">Antibiotics (cytotoxic)</a></li><li id="_41001i507"><a href="41001i507.htm" title="Antimetabolites">Antimetabolites</a></li><li><a href="41001i513.htm" title="Pentostatin">Pentostatin</a></li><li id="_41001i512"><a href="41001i512.htm" title="Platinum Compounds">Platinum Compounds</a></li><li><a href="41001i514.htm" title="Procarbazine">Procarbazine</a></li><li><a href="41001i885.htm" title="Temozolomide">Temozolomide</a></li><li><a href="41001i815.htm" title="Vincristine">Vincristine</a></li><li id="_41001i515"><a href="41001i515.htm" title="Taxanes">Taxanes</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i995.htm">Previous: Cranberry Juice</a> | <a class="top" href="41001i500.htm#">Top</a> | <a accesskey="]" href="41001i1205.htm">Next: Eribulin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>